Table 1.
Selected CAR T-cell trials for multiple myeloma
| Antigen | Trial site/company | Phase | Accrual | n | ORR (%) | CR (%) | Identifier |
| BCMA | NCI | I | Completed | 16 | 81* | 13 | NCT02215967 |
| UPenn/Novartis | I | Completed | 25 | 48 | 8 | NCT02546167 | |
| Celgene/Bluebird | I | Completed | 33 | 85 | 45 | NCT02658929 | |
| Celgene/Bluebird | I | Ongoing | 12# | 83 | 25 | NCT03274219 | |
| Nanjing Legend | I/II | Ongoing | 57 | 88 | 68 | NCT03090659 | |
| Memorial Sloan-Kettering Cancer Center/Juno | I | Ongoing | 11 | 64 | 0 | NCT03070327 | |
| Fred Hutchinson Cancer Research Center/Juno | I | Ongoing | 11 | 100 | 36 | NCT03338972 | |
| Celgene (ex Juno) | I/II | Ongoing | 44 | 82 | 27 | NCT03430011 | |
| Poseida | I/II | Ongoing | 19 | 43 | 5 | NCT03288493 | |
| Celgene | II | Ongoing | NCT03601078 | ||||
| Celgene | III | Ongoing | NCT03651128 | ||||
| Autolus Limited | I/II | Ongoing | NCT03287804 | ||||
| Cartesian | I/II | Ongoing | NCT03448978 | ||||
| κ light chain | Baylor University | I | Completed | 7 | 0 | 0 | NCT00881920 |
| CD138 | Chinese PLA General Hospital | I/II | Completed | 5 | 20 | 0 | NCT01886976 |
| Lineberger Comprehensive Cancer Center | I | Ongoing | NCT03672318 | ||||
| CD38 | Sorrento/Celularity | I | Ongoing | NCT03464916 | |||
| Shenzhen Geno-Immune Medical Institute, China | I/II | Ongoing | NCT03271632 | ||||
| SLAMF7 | NCI | I | Ongoing | NCT03958656 | |||
| GPRC5D | Preclinical |
CAR, chimeric antigen receptor; BCMA, B-cell maturation antigen; GPRC5D, G-protein-coupled receptor, class C group 5 member D; NCI, National Cancer Institute; UPenn, University of Pennsylvania; PLA, People’s Liberation Army; ORR, overall response rate; CR, complete response.
*
81% (13 of 16) ORR at the highest dose of 9×106 CAR T cells/kg.
#
All 12 subjects were treated at the lowest dose of 1.50×108 cells/kg